• News
  • SAN DIEGO
  • BioTech

Regen BioPharma files FDA application for anemia drug

Regen BioPharma, a wholly owned subsidiary of San Diego-based Bio-Matrix Scientific Group Inc. (PNK: BMSN), announced Tuesday the filing of an Investigational New Drug application with the Food and Drug Administration to initiate clinical trials assessing the company's HemaXellerate I stem cell drug in patients with drug-refractory aplastic anemia.

HemaXellerate I is a patient-specific composition of cells that have previously been demonstrated to repair damaged bone marrow and stimulate production of blood cells based on previous animal studies.

If the clinical trial is successful, the company plans to expand use of HemaXellerate I to other conditions associated with bone marrow dysfunction, with the overall goal of entering the hematopoietic growth factor market.

This market is substantial in size and currently includes drugs such as Neupogen, Neulasta, Leukine and Revolade.

RELATED ARTICLES:

La Jolla Pharmaceutical receives patent for pectin composition

Tandem Diabetes Care acquires ownership of 23 patents

Isis Pharma shares rise on Kynamro approval

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

Bio-Matrix Scientific Group

Company Website

1649 Dartmouth
Chula Vista, CA 91913

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
BMSN
0.0
  0.0  
+ 0.00%
22,879,050,000
0.0
0.0

Bio-Matrix Scientific Group Executive(s):

David Koos

  • Chairman, Chief Executive Officer, President

Similar Companies

NAICS - 325414 - Biological Product (except Diagnostic) Manufacturing
NAICS - 423450 - Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers